Dimerix successfully enters into non-dilutive facility agreements to access A$34 million

Dimerix 成功签署非稀释性融资协议，获得 3,400 万澳元资金

[1]

[1]

with a syndicate of Australian and U.S. independent lenders, including the previously announced initial facility of A$10 million

与一个由澳大利亚和美国独立贷款人组成的银团合作，包括此前宣布的初始融资额度1,000万澳元

[2]

[2]

Facility terms for all Lenders substantially consistent with the previously announced loan facility;

所有贷款人的融资条款与先前宣布的贷款安排基本一致；

[2]

[2]

with minor amendments made to the SKIPTAN agreement to standardise key terms across all Lenders (other than in respect of security, refer to Appendix 1)

对SKIPTAN协议作出轻微修订，以使所有贷款人之间的关键条款标准化（担保事项除外，参见附录1）

Dimerix has elected to drawdown only 50% of the amount committed initially, which is considered sufficient to complete all currently planned activities, including delivery of the ACTION3 Phase 3 trial of DMX-200 and continued advancement of the Phase 2 trial of DMX-652 in Acute Kidney Injury

Dimerix 已选择仅提取最初承诺金额的 50%，该金额被认为足以完成所有当前计划的活动，包括推进 DMX-200 的 ACTION3 三期临床试验以及继续推进 DMX-652 在急性肾损伤方面的二期临床试验。

[3]

[3]

The facility provides the option to secure up to A$50m in total commitments on or before 31 March 2027, should Dimerix elect to do so; noting the Company currently has no plans access this additional funding

该融资安排允许Dimerix选择在2027年3月31日或之前获得总额高达5,000万澳元的承诺额度；但需注意，公司目前并无计划动用这笔额外资金。

Facility provides Dimerix with considerable financial flexibility without diluting shareholders

该融资安排为Dimerix提供了可观的财务灵活性，且不会稀释股东权益

MELBOURNE, Australia

澳大利亚墨尔本

,

，

Sept. 4, 2026

2026年9月4日

/PRNewswire/ -- Dimerix Limited (ASX: DXB, 'Dimerix') a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has successfully secured non-dilutive loan facility agreements ('Loan Agreements') with a group of Australian and U.S. based lenders to access up to A$34 million.

/美通社/ -- Dimerix Limited（澳大利亚证券交易所代码：DXB，简称“Dimerix”）是一家处于临床阶段的生物制药公司，致力于开发肾脏疾病治疗药物。该公司很高兴地宣布，已成功与一组澳大利亚和美国的贷款机构签订非稀释性贷款融资协议（“贷款协议”），以获得高达3,400万澳元的资金。

[1]

[1]

(see key terms in Appendix 1), including the existing A$10 million facility agreement with SKIPTAN.

（参见附录1中的关键术语），包括与SKIPTAN现有的1000万澳元融资协议。

[2]

[2]

'We are delighted with the support received from lenders across both Australia and the United States, reflecting growing confidence in Dimerix, our clinical programs and our mission to improve outcomes for patients suffering from serious kidney diseases. The successful entry into this facility provides Dimerix with the financial flexibility needed to execute our planned development activities without dilution for shareholders..

我们对从澳大利亚和美国两地贷款方获得的支持感到欣喜，这反映出市场对Dimerix、我们的临床项目以及我们改善严重肾病患者治疗结果的使命日益增强的信心。成功获得该融资额度为Dimerix提供了所需的财务灵活性，使我们能够执行计划中的开发活动，同时避免对股东权益造成稀释。

Importantly, we have taken a disciplined approach and elected to access only the funding considered required to complete our currently planned activities. We believe this is in the best interests of shareholders, including completion of both the ACTION3 Phase 3 trial of DMX-200 and the Phase 2 trial of DMX-652 in Acute Kidney Injury..

重要的是，我们采取了审慎的策略，仅获取完成当前计划活动所需的资金。我们认为这符合股东的最佳利益，包括完成DMX-200的ACTION3 III期临床试验以及DMX-652在急性肾损伤中的II期临床试验。

Kidney disease is now recognised as one of the fastest-growing causes of death globally, and yet treatment options remain limited for many patients. As a company dedicated exclusively to kidney disease, Dimerix remains focused on developing new treatment options that have the potential to improve and extend the lives of patients in urgent need.'.

肾脏疾病现在被公认为全球增长最快的死亡原因之一，然而许多患者的治疗选择仍然有限。作为一家专注于肾脏疾病的公司，Dimerix 仍然致力于开发新的治疗方案，这些方案有可能改善并延长急需治疗的患者的生命。

Dr Nina Webster, CEO & Managing Director, Dimerix

尼娜·韦伯斯特博士，Dimerix 首席执行官兼董事总经理

Non-dilutive funding flexibility

非稀释性融资灵活性

The facility has been established to support Dimerix's ongoing clinical development programs and provides the Company with significant financial flexibility while advancing its late-stage pipeline.

该融资安排旨在支持 Dimerix 正在进行的临床开发计划，并在推进其后期研发管线的同时，为公司提供显著的财务灵活性。

The terms of the facility for the new lenders are substantially similar to those previously announced for the SKIPTAN facility (ASX: 17 July 2026), with SKIPTAN terms amended to ensure alignment (see Appendix 1 for details). The facility provides the flexibility for Dimerix to elect to take further commitments for up to a total of A$50m on or before 31 March 2027..

新贷款方的融资条款与此前公布的SKIPTAN融资条款（澳交所公告，2026年7月17日）基本一致，并对SKIPTAN条款进行了修订以确保一致性（详见附录1）。该融资安排为Dimerix提供了灵活性，使其可选择在2027年3月31日或之前追加承诺，使总承诺金额最高达到5,000万澳元。

Importantly, Dimerix has elected to initially drawdown only the amount of funding considered required to complete its currently planned activities, being 50% of the currently committed funds.

重要的是，Dimerix 已选择仅提取完成其当前计划活动所需的资金金额，即目前承诺资金的 50%。

[3]

[3]

This disciplined approach to capital management minimises financing costs and shareholder dilution, while maintaining the flexibility to access additional capital under the facility if required in the future.

这种纪律严明的资本管理方法最大限度地降低了融资成本和股东权益稀释，同时保留了在必要时通过该融资机制获取额外资本的灵活性。

Funded for ACTION3 trial and DMX-652 development activities

为ACTION3试验和DMX-652开发活动提供资金

Based on the Company's present operating plans and anticipated expenditure, Dimerix confirms that it is funded through to completion of the ACTION3 Phase 3 trial in DMX-200, as well as the planned Phase 2 clinical trial in DMX-652, through:

根据公司目前的运营计划和预期支出，Dimerix 确认其资金足以支持完成 DMX-200 的 ACTION3 三期临床试验以及 DMX-652 的计划二期临床试验，具体通过以下方式：

[3]

[3]

Existing cash reserves; and

现有现金储备；以及

A$34 million

3400万澳元

[1]

[1]

via the binding Loan Agreements, with receipt of the initial 50% draw-down anticipated in September 2026 and the remainder to take place at the Company's discretion on or before 31 March 2027.

通过签署的贷款协议，预计于2026年9月提取首笔50%的贷款，其余部分由公司自行决定在2027年3月31日或之前提取。

The facility is anticipated to be repaid through existing future licensee milestone payment(s), potential new license fees and/or capital market access. Dimerix has secured five commercial partners across major markets, generating A$81 million in upfront payments received to date and creating the opportunity for a further A$237 million in development milestone payments ahead of commercial launch..

预计该设施将通过现有的未来被许可方里程碑付款、潜在的新许可费以及/或进入资本市场来偿还。Dimerix 已在主要市场 secured 五家商业合作伙伴，迄今已产生 8,100 万澳元的预付款收入，并为在商业发布前获得额外 2.37 亿澳元的开发里程碑付款创造了机会。

[4]

[4]

Advancing a Leading Kidney Disease Pipeline

推进领先的肾病产品管线

Kidney disease is among the fastest-growing causes of death worldwide and represents a significant and increasing healthcare burden. Despite this growing prevalence, many forms of kidney disease continue to have limited treatment options available for patients.

肾脏疾病是全球增长最快的死亡原因之一，并构成了显著且日益加重的医疗负担。尽管其患病率不断上升，许多类型的肾脏疾病仍缺乏充足的治疗选择供患者使用。

[5]

[5]

,

，

[6]

[6]

Dimerix is uniquely focused on kidney diseases, with a pipeline designed to address significant unmet medical needs. The Company's lead program, DMX-200, is currently being evaluated in the fully recruited global ACTION3 Phase 3 clinical trial in patients with FSGS - a serious, rare kidney disease that can lead to kidney failure and the need for dialysis or transplantation..

Dimerix 独特地专注于肾脏疾病，其研发管线旨在满足重大的未竟医疗需求。公司的核心项目 DMX-200 目前正在一项已全面完成入组的全球性 ACTION3 三期临床试验中进行评估，该试验针对的是局灶节段性肾小球硬化症（FSGS）患者——这是一种严重的罕见肾脏疾病，可能导致肾衰竭，并需要透析或肾移植。

Dimerix is also advancing DMX-652 for Acute Kidney Injury, a condition associated with significant morbidity, mortality and healthcare costs worldwide. The Phase 2 clinical program is designed to evaluate the potential of DMX-652 in preventing kidney injury and preserving renal function, following cardiac surgery..

Dimerix 也在推进 DMX-652 用于急性肾损伤的治疗，这是一种与全球高发病率、高死亡率及高昂医疗成本相关的疾病。二期临床项目旨在评估 DMX-652 在心脏手术后预防肾损伤和保护肾功能方面的潜力。

Potential catalysts

潜在催化剂

As Dimerix advances its pivotal, fully recruited ACTION3 Phase 3 trial for DMX-200 toward what is anticipated to be a major value-creating event if successful, the Company has simultaneously strengthened its growth profile through the recent acquisition of DMX-652 and its ongoing advancement into Phase 2 clinical development.

随着 Dimerix 推进其 DMX-200 的关键性、已完成入组的 ACTION3 III 期临床试验，并预期若成功将带来重大的价值提升事件，该公司同时通过近期收购 DMX-652 并持续推动其进入 II 期临床开发，强化了其增长前景。

Progress and positive outcomes from the DMX-652 development program have the potential to create substantial additional shareholder value, diversify Dimerix's clinical pipeline, and deliver multiple near- and medium-term catalysts for investors..

DMX-652 开发计划的进展和积极成果有望创造巨大的额外股东价值，丰富 Dimerix 的临床产品线，并为投资者提供多个近期和中期的催化剂。

The entry into the A$34 million

进入价值3400万澳元的

[1]

[1]

facility the subject of the Loan Agreements is expected to support these important clinical milestones and further strengthen Dimerix's position as a leading kidney disease-focused biotechnology company.

贷款协议项下的融资预计将支持这些重要的临床里程碑，并进一步巩固 Dimerix 作为专注于肾脏疾病的领先生物技术公司的地位。

Authorised for lodgement by the Board of Dimerix

经Dimerix董事会授权提交

—END—

—完—

For further information, please visit our website at

如需更多信息，请访问我们的网站：

www.dimerix.com

www.dimerix.com

.

。

Follow Dimerix on

在以下平台关注 Dimerix

LinkedIn

领英

and

和

X

X

About Dimerix

关于 Dimerix

Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The Company's lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options.

Dimerix Limited（澳交所代码：DXB）是一家处于临床阶段的生物制药公司，专注于开发针对存在重大未满足医疗需求的肾脏疾病的新疗法。公司的核心项目DMX-200目前正处于治疗局灶节段性肾小球硬化（FSGS）的III期临床研究阶段。FSGS是一种严重且危及生命的罕见肾脏疾病，现有治疗选择有限。

In addition, Dimerix is advancing a Phase 2 program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. With a growing network of five commercial partners supporting global development and future market access, Dimerix is committed to expanding its reach and delivering innovative treatments to as many patients as possible worldwide while creating long-term value for shareholders.

此外，Dimerix 正在推进一项针对急性肾损伤（AKI）的二期临床项目，进一步强化其在高需求肾脏病适应症领域的产品管线。凭借由五家商业合作伙伴组成的日益壮大的网络，支持其全球开发及未来市场准入，Dimerix 致力于扩大覆盖范围，为全球尽可能多的患者提供创新疗法，同时为股东创造长期价值。

For more information, please visit the company's website at .

欲了解更多信息，请访问公司网站：。

www.dimerix.com

www.dimerix.com

.

。

About DMX-200 in FSGS

关于FSGS中的DMX-200

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli - the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury.

局灶性节段性肾小球硬化（FSGS）是一种罕见且严重的肾脏疾病，其特征是肾小球（肾脏的过滤单位）部分区域出现进行性瘢痕形成（硬化）。这种瘢痕形成导致蛋白尿、肾功能进行性丧失，并常引发终末期肾病。人们日益认识到，FSGS 具有炎症成分，单核细胞和巨噬细胞的活化会加剧肾小球损伤。

In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children..

在美国，估计有超过4万人患有局灶节段性肾小球硬化症（FSGS），其中包括成人和儿童。

[7]

[7]

There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years.

在美国，尚无专门针对局灶节段性肾小球硬化（FSGS）的获批疗法，疾病管理依赖于非特异性免疫抑制和支持治疗。对于进展性或治疗抵抗性FSGS患者，从诊断到终末期肾病的平均时间可短至五年。

Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,.

即使在接受肾移植的患者中，疾病复发率也高达60%。

[8]

[8]

underscoring the urgent need for new, disease-modifying treatments.

凸显了对新型疾病修饰疗法的迫切需求。

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan.

DMX-200 是一种趋化因子受体（CCR2）拮抗剂，用于已接受血管紧张素II型1受体（AT1R）阻滞剂治疗的患者，而AT1R阻滞剂是高血压和肾脏疾病的标准治疗方案。DMX-200 在多个地区拥有已授予的专利保护，有效期至2032年；此外，已在全球提交专利申请，可能将专利保护期延长至2042年。同时，该药物在美国、欧洲、英国和日本已获得孤儿药资格认定。

[9]

[9]

.

。

About DMX-652 in Acute Kidney Injury

关于DMX-652在急性肾损伤中的应用

Acute kidney injury (AKI) is a prevalent and severe clinical syndrome of substantial unmet need. It can arise from several high-risk clinical settings including, most notably, cardiac surgery and sepsis and is characterised by a rapid decline in kidney function (within hours), often resulting in high morbidity and mortality.

急性肾损伤（AKI）是一种普遍且严重的临床综合征，存在巨大的未满足医疗需求。它可由多种高风险临床情况引发，其中最显著的是心脏手术和脓毒症，其特征是肾功能在短时间内（数小时内）迅速下降，常导致高发病率和高死亡率。

The current addressable patient population is estimated to be approximately 260,000 across the major markets of United States, Germany, France, Italy, Spain and United Kingdom per annum,.

据估计，在美国、德国、法国、意大利、西班牙和英国等主要市场，当前每年可触及的患者人群约为260,000人。

[10]

[10]

,

，

[11]

[11]

making this indication a potential orphan designation. AKI represents a significant clinical burden. There are no approved therapies for AKI, which is associated with rapid kidney function decline within hours, increased risk of chronic kidney disease and long-term kidney complications.

这使得该适应症有可能获得孤儿药认定。急性肾损伤（AKI）带来了沉重的临床负担。目前尚无针对AKI的获批疗法，而AKI与数小时内肾功能迅速下降、慢性肾病风险增加以及长期肾脏并发症相关。

DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. DMX-652, which is a small molecule delivered as an oral once daily capsule, is designed to support mitochondrial quality control in injured kidney cells, a mechanism indicated in the progression of AKI caused by ischaemia (lack of blood flow resulting in oxygen starvation), toxins or sepsis related causes, as well as in other renal and non-renal indications.

DMX-652 是一种选择性 USP30 抑制剂，USP30 是一种线粒体酶，可减缓受损线粒体的清除。DMX-652 是一种小分子药物，以每日一次口服胶囊的形式给药，旨在支持受伤肾细胞中的线粒体质量控制。该机制在由缺血（血流不足导致缺氧）、毒素或脓毒症相关原因引起的急性肾损伤（AKI）进展中发挥作用，同时也涉及其他肾脏及非肾脏适应症。

The DMX-652 acquisition includes the composition of matter patent, an open IND in the US with a Phase 2 clinical trial protocol which has received approval to proceed by the US Food and Drug Administration (FDA), as well as sufficient pharmaceutical grade (GMP) drug product for the Phase 2 trial and all manufacturing methodology.

DMX-652的收购包括物质组成专利、在美国的一项开放的新药临床试验申请（IND），其二期临床试验方案已获得美国食品药品监督管理局（FDA）批准 proceed，以及用于二期试验的足够制药级（GMP）药物产品和所有生产工艺方法。

The Phase 2 trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function..

II期临床试验旨在评估DMX-652在预防肾损伤和保护肾功能方面的潜力。

Dimerix Forward Looking Statement

Dimerix前瞻性声明

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements.

本发布包含前瞻性陈述，这些陈述受风险和不确定性的影响。尽管管理层认为，目前前瞻性陈述中所反映的预期是合理的，但Dimerix无法保证这些预期将被证实为正确。提醒读者不要过度依赖前瞻性陈述。

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report..

实际结果可能与预期存在重大差异。原因可能包括与药物开发和生产相关的风险、监管流程固有的风险、临床试验的延误、临床试验的结果、合同风险、与专利保护相关的风险、未来资本需求或其他一般性风险或因素，包括但不限于 Dimerix Limited 最新年度报告中列出的那些因素。

Appendix 1

附录1

Key Terms of the Loan Facility Agreements

贷款融资协议的关键条款

Lenders

贷款人

Various independent and unrelated U.S. and Australia-based investors, as well as SKIPTAN Pty Ltd (A$2,000,000) and SKIPTAN Pty Ltd as Trustee for the P&M Meurs Family Trust (A$10,000,000) (collectively the '

多家独立且无关联的美国和澳大利亚投资者，以及 SKIPTAN Pty Ltd（200 万澳元）和作为 P&M Meurs 家族信托受托人的 SKIPTAN Pty Ltd（1,000 万澳元）（统称为“

Lenders'

贷款人的

). The SKIPTAN entities are each an associate of Mr Peter Meurs, a substantial shareholder of Dimerix, and a related party of Dimerix.

）。SKIPTAN各实体均为Dimerix主要股东Peter Meurs先生的联营方，且构成Dimerix的关联方。

Facility

设施

Collectively A$34 million

共计3400万澳元

[1]

[1]

(of which 50% must be drawn down by Dimerix by 18 September 2026, and the remainder at Dimerix's discretion (in whole or in part) up to 31 March 2027). Dimerix has the option to take further commitments for up to a total of A$50m before March 2027. Dimerix may draw down on the facility by providing a drawdown notice to the Lender not less than 15 business days prior to the proposed drawdown date (or 5 business days for the first draw down of 50% of the amount committed).

（其中50%须由Dimerix在2026年9月18日之前提取，剩余部分可由Dimerix自行决定在2027年3月31日之前全部或部分提取）。在2027年3月之前，Dimerix有权选择增加承诺额度，使总承诺额度最高达到5,000万澳元。Dimerix可通过向贷款人发出提款通知来提取融资款项，该通知须在拟议提款日前至少15个工作日发出（但对于首次提取已承诺金额的50%，则需提前5个工作日发出）。

If Dimerix does not draw down the full facility amount by 31 March 2027, the balance lapses and cannot be drawn upon..

如果 Dimerix 未在 2027 年 3 月 31 日之前提取全部融资额度，剩余额度将失效且不得再行提取。

Term

术语

Facility amount drawn down and received by Dimerix plus accrued interest to be repaid by 17 January 2028 (refer to repayment term below).

Dimerix已提取并收到的融资额度本金及应计利息，须于2028年1月17日前偿还（参见下述还款条款）。

Use of Funds

资金使用

Extend cash runway to support: DMX-200 expanded access programs; DMX-200 commercial manufacturing readiness; clinic-ready pipeline expansion in rare/renal disease, including DMX-652.

延长现金跑道以支持：DMX-200扩大可及性项目；DMX-200商业化生产准备；罕见病/肾病领域临床阶段管线的扩展，包括DMX-652。

Interest rate

利率

10% per annum, compounding annually: applies only to the facility amount drawn down and received by Dimerix. No interest shall accrue on the milestone participation (refer below).

年利率10%，按年复利：仅适用于Dimerix已提取并收到的融资额度。里程碑参与款项不计利息（见下文）。

Security

安全

The unrelated Lenders (being all Lenders other than the SKIPTAN entities) hold the benefit of security granted by the Company and Dimerix Biosciences Pty Ltd pursuant to a General Security Deed consistent with industry standard. The SKIPTAN entities, as related parties, remain unsecured pending Dimerix obtaining a waiver of Listing Rule 10.1 from ASX, or shareholder approval to grant security to the Lender in line with the announcement dated 17 July 2026..

非关联贷款方（即除SKIPTAN实体外的所有贷款方）享有由公司及Dimerix Biosciences Pty Ltd根据符合行业惯例的一般担保契据授予的担保权益。作为关联方，SKIPTAN实体在Dimerix获得澳大利亚证券交易所（ASX）对《上市规则》第10.1条的豁免，或股东批准按照2026年7月17日公告的内容向贷款方授予担保之前，仍为无担保债权人。

[2]

[2]

The security interest, as applicable, will only apply to principal drawn down by Dimerix and accrued interest. It will not apply to the milestone participation (refer below), which will remain an unsecured obligation of the Company.

担保权益（如适用）仅适用于Dimerix提取的本金及应计利息。该担保权益不适用于里程碑参与款项（见下文），该款项仍为公司的无担保债务。

Repayment

还款

Dimerix may repay the facility amount received any time until the repayment date (17 January 2028), with a commensurate reduction in earned interest (10% p.a. compounding annually to the repayment date).

Dimerix 可在还款日（2028年1月17日）之前的任何时间偿还所获得的融资款项，相应地，应计利息将按比例减少（年利率为10%，按年复利计算至还款日）。

Milestone participation

里程碑参与

Unsecured right of the Lenders, including any new lenders, to an aggregate of 30% of each milestone payment received by Dimerix under DMX-200 commercial license agreements, capped in aggregate at 2.0x the amount drawn down and received by Dimerix from the Lenders. Each Lender, including any new lender, is to participate in each milestone payment in their respective proportion of the overall funding drawn down..

贷款人（包括任何新加入的贷款人）对Dimerix根据DMX-200商业许可协议收到的每笔里程碑付款享有无担保权利，有权获得合计高达30%的款项，但所有贷款人累计获得的总额以Dimerix从贷款人处提取并实际收到的资金总额的2.0倍为上限。每位贷款人（包括任何新加入的贷款人）应按其在整体已提取融资中所占的比例参与每笔里程碑付款的分配。

Other terms

其他条款

The Loan Agreement otherwise contains terms typical for an agreement of this kind, including representations and warranties from the Company, default provisions (including without limitation in respect to the occurrence of an insolvency event, a material adverse change or breach of obligations by the Company under the Loan Agreement) and undertakings by the Company, including to preserve the potential for receipt of milestones as described above..

除上述内容外，本贷款协议包含此类协议常见的条款，包括公司的陈述与保证、违约条款（包括但不限于就发生破产事件、重大不利变化或公司违反贷款协议项下义务的情形）以及公司的承诺，其中包括保持获得上述里程碑款项的可能性。

References

参考文献

[1]

[1]

Based on 60 day Wall Street Journal average exchange rate of 1 USD = 1.4228 AUD from 1 July - 1 September 2026

根据2026年7月1日至9月1日《华尔街日报》公布的60天平均汇率，1美元=1.4228澳元

[2]

[2]

ASX announcement 17 July 2026

澳交所公告 2026年7月17日

[3]

[3]

Based on current anticipated spend, activities and exchange rates; should activities, spend or exchange rates change, this could materially impact the cash runway of the Company

根据当前预期的支出、业务活动及汇率水平；若业务活动、支出或汇率发生变动，可能会对公司的现金跑道产生重大影响。

[4]

[4]

ASX Investor Presentation released 06 August 2026

ASX投资者演示文稿于2026年8月6日发布

[5]

[5]

Editorial, Time to sound the alarm about the hidden epidemic of kidney disease, Nature

社论，是时候为肾脏疾病的隐性流行敲响警钟了，《自然》

628, 7-8 (2024) doi:

628, 7-8 (2024) doi:

https://doi.org/10.1038/d41586-024-00961-5

https://doi.org/10.1038/d41586-024-00961-5

[6]

[6]

The United States Renal Data System (USRDS)

美国肾脏数据系统（USRDS）

Annual Report 2023; (2022 & 2023 estimates based on average growth 2001-2021)

2023年年度报告；（2022年和2023年的估算基于2001-2021年的平均增长率）

[7]

[7]

Nephcure FSGS Facts (

Nephcure FSGS 事实（

https://nephcure.org/

https://nephcure.org/

)

）

[8]

[8]

Front. Immunol., (July 2019) |

《免疫学前沿》，2019年7月 |

https://doi.org/10.3389/fimmu.2019.01669

https://doi.org/10.3389/fimmu.2019.01669

[9]

[9]

ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025

澳交所公告发布日期：2015年12月14日、2018年11月21日、2021年6月7日、2025年9月30日

[10]

[10]

Demirjian S, Bashour CA, Shaw A, et al. Predictive Accuracy of a Perioperative Laboratory Test–Based Prediction Model for Moderate to Severe Acute Kidney Injury After Cardiac Surgery. JAMA 2022;327:956–64.

Demirjian S, Bashour CA, Shaw A, 等. 基于围手术期实验室检查的预测模型对心脏手术后中重度急性肾损伤的预测准确性. JAMA 2022;327:956–64.

https://doi.org/10.1001/jama.2022.1751

https://doi.org/10.1001/jama.2022.1751

.

。

[

[

11]

11]

Hobson C, Ruchi R, Bihorac A. Perioperative Acute Kidney Injury. Crit Care Clin 2017;33:379–96.

霍布森 C，鲁奇 R，比霍拉克 A。围手术期急性肾损伤。《重症监护临床》2017；33:379–96。

https://doi.org/10.1016/j.ccc.2016.12.008

https://doi.org/10.1016/j.ccc.2016.12.008

SOURCE Dimerix Limited

来源：Dimerix Limited

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，附带

Request a Demo

申请演示